ZICAM and VIRA 38

Dr Hensley is an international known innovator, visionary, entrepreneur, scientific with a global footprint. He has been featured in USA Today, Time Magazine and has appeared on CNBC Squawk Box Asia. Dr Hensley, discover and development ZICAM cold and remedy (considering by many “the cure for the common Cold”), founded ZICAM LLC and went on to market this iconic American brand.

Hensley refined the technology that emerged from his "Taiwan and Hong Kong days" which ultimately led to the development of a suite of broad spectrum anti-viral products.  

In the early 2000s, Hensley partnered with a Hong Kong group to form the Hong Kong–based cosmetic company Jovell, Inc. The company currently has over thirty products on the market, and has retail boutique shops and cosmetic counters in major department stores throughout Hong Kong and other parts of Asia.

In 2007, Hensley founded Nasal Therapeutics, Inc. to develop and market nasal spray technologies and products. That same year, Nasal Therapeutics, Inc. entered into a licensing agreement with Therabiogen, Inc., which allowed them the exclusive right to manufacture, market and sell two nasal therapeutic nasal sprays, Theramax Cold and Flu Relief and Theramax Allergy Relief. As a result of the deal, Hensley became Therabiogen's largest shareholder.

Subsequently, Hensley developed a new platform technology based on his theory of altered functioning of EAA transport proteins in neurodegenerative diseases. From this platform, Hensley developed a series of therapies including one for the treatment for migraine headaches. Hensley subsequently formed Migranade, Inc. to further develop the migraine treatment for the market. Hensley and his company received the National Drug Code (NDC) from the FDA which cleared the therapeutic for sale in the United States.